Skip to main navigationSkip to main content
The University of Southampton
Centre for Clinical and Experimental PsychopharmacologyGAD Research

Published work

 

Here you can see a regularly updated list of the published work from our research centre.

1. Baldwin DS, Leonard BE. Anxiety Disorders. In: Leonard BE. Modern Trends in Pharmacopsychiatry. 2013; Vol 29. Krager: Basel.

2. Baldwin DS, Pallanti S, Zwanzger P. Developing a European research network to address unmet needs in anxiety disorders. Neuroscience and Biobehavioural Reviews 2013; pii: S0149-7634(13)00010-9. Epub ahead of print.

3. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatric Disease and Treatment 2013; volume 9 Pages 883 – 892.

4. Baldwin DS, Meron D, Tiwari N. Update on pharmacological treatment of anxiety disorders: where is the greatest room for improvement? European Psychiatry 2011; 26 (suppl.): SUO201.

5. Ainsworth B, Eddershaw R, Meron D, Baldwin DS, Garner M. The effect of focused attention and open monitoring mediation on attention network function in healthy volunteers. Psychiatry Research 2013; 1226-1231.

6. Ainsworth B, Garner M. Attention control in mood and anxiety disorders: evidence from the antisaccade task. Human Psychopharmacology: Clinical and Experimental 2013; 28, 275-280.

7. Tiwari N, Baldwin DS. Yogic breathing techniques in the management of anxiety and depression: systematic review of evidence of efficacy and presumed mechanism of action. Mind and Brain. 2012; 3(1).

8. Bolognesi F, Baldwin DS, Ruini C. Psychological interventions in the treatment of generalized anxiety disorder: a structured review. Journal of Psychopathology. Accepted for publication.

9. Baldwin DS, Pallanti S, Zwanzger P. Developing a European research network to address unmet needs in anxiety disorders. Neuroscience and Biobehavioral Reviews 2013; 37: 2312-2317

10. Hou R, Teng Z, Baldwin DS. Potential neuroimmunological targets in the treatment of anxiety disorders. In: Baldwin DS, Leonard B (eds). Anxiety Disorders. Karger Press, Basel. Accepted for publication.

11. Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology 2012; 22: 841-843. [IF 4.307]

12. Brandish EK, Baldwin DS. Anxiety disorders. MEDICINE. 2012, 40: 599-606. [IF 5.02]

13. Hou R, Baldwin DS. A neuropsychoimmunological perspective on anxiety disorders. Human Psychopharmacology-Clinical and Experimental 2012; 27: 6-14.

14. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 2011; 14: 697-710.

15. Baldwin DS, Lopes AV. Agomelatine in the treatment of mood and anxiety disorders. British Journal of Hospital Medicine 2010; 71: 153-156.

16. Baldwin DS, Ajel KI, Garner MJ. Anxiety Disorders. MEDICINE 2008; 36: 415-421.

17. Garner M, Attwood A, Baldwin DS, James A, Munafo MR. Inhalation of 7.5% carbon dioxide increases threat processing in humans. Neuropsychopharmacology 2011; 35, 1-6.

In recent years there have been many advances in the areas of genetics, temperament research, neuropsychology and neuroimaging, and these provide some understanding of the origin and maintenance of anxiety in healthy volunteers and clinical samples.

Privacy Settings